Back

Contextualising ATTR-CM clinical trial designs

29 August 2026 (12:50 - 13:05)
Organised by: Logo
Congress Presentation Part of: In focus: the next era of transthyretin amyloid cardiomyopathy (ATTR-CM) management European Society of Cardiology ESC Professional Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Professor Scott Solomon

Brigham and Women's Hospital, Harvard Medical School, Boston (United States of America)

4 More presentations in this session

Presentation thumbnail
Welcome and introductions
Professor S. Solomon (Boston, US)
Presentation thumbnail
Expert perspectives on the evolving ATTR-CM landscape
Professor R. Witteles (Stanford, US)
Presentation thumbnail
Evidence-based ATTR-CM care in practice
Professor O. Azevedo (Guimaraes, PT)
Presentation thumbnail
Q&A and closing
Professor S. Solomon (Boston, US)

Access the full session

Session thumbnail
In focus: the next era of transthyretin amyloid cardiomyopathy (ATTR-CM) management

The Event

Event poster

ESC Congress 2026

29 August 2026 12:50 CET
You may be interested in
thumbnail
Congress Session
ATTRibutes of change: advances in treating and monitoring ATTR-CM
17 May 2025
thumbnail
Congress Presentation
Design and rationale of a phase 3 study to evaluate the efficacy and safety of nucresiran (ALN-TTRsc04) in patients with transthyretin amyloidosis with cardiomyopathy
19 May 2025
thumbnail
Congress Presentation
Transthyretin-directed antisense oligonucleotide therapy effects on ATTRv myocardiopathy
20 May 2023
thumbnail
Congress Session
Evolving treatment paradigms in heart failure: from SGLT2 inhibition to transthyretin stabilisation and beyond
20 May 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources